Clinical Trials
8 trialsNCT00355238 2023-12-01
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT04395612 2021-05-21
CQGOG0101
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT01253668 2021-04-13
Brivanib Metastatic Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT01367275 2020-09-03
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03516071 2019-09-04
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT01267253 2019-03-20
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00888173 2017-12-06
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT00633789 2015-10-09
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
Phase 2 Completed